Premium
Resectable recurrent colorectal liver metastasis: can radiofrequency ablation replace repeated metastasectomy?
Author(s) -
Mao Rui,
Zhao JianJun,
Bi XinYu,
Zhang YeFan,
Han Yue,
Li ZhiYu,
Zhao Hong,
Cai JianQiang
Publication year - 2019
Publication title -
anz journal of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.426
H-Index - 70
eISSN - 1445-2197
pISSN - 1445-1433
DOI - 10.1111/ans.15080
Subject(s) - medicine , metastasectomy , radiofrequency ablation , general surgery , metastasis , ablation , surgery , cancer
Background Percutaneous radiofrequency ablation (RFA) is used as a first‐line treatment for colorectal liver metastases that recur after first liver resection in our institution. We aim to evaluate its therapeutic efficacy compared to repeated surgical resection. Methods A retrospective review was performed in 104 patients treated with curative intent for resectable recurrent colorectal liver metastases. Results Sixty‐one patients underwent RFA and 43 patients underwent surgery. The overall recurrence rates were 82% in the RFA group and 65.1% in the resection group ( P = 0.05). The local recurrence rate on a lesion‐basis was markedly higher after RFA than that after resection (16.7% versus 7.3%, P = 0.04). The difference remained significant in patients with a maximum lesion diameter >3 cm (24.5% versus 7.6%, P = 0.01). RFA treatment was independently associated with recurrence on multivariate analyses ( P = 0.01). 69.7% of RFA patients and 42.6% of surgery patients with intrahepatic recurrence were amenable to repeated local treatment ( P = 0.05), leading to the equivalent actuarial 3‐year progression free survival rates (RFA: 29.1% versus Resection: 33.1%, P = 0.48) and 5‐year overall survival rates in the two treatment groups (RFA: 33% versus Resection: 28.4%, P = 0.36). Conclusions Surgery remains the treatment of choice for resectable recurrence. RFA may offer similar benefit in selected patients.